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BACKGROUND: Little is known about recent trends in surveillance among the more than 1 million US colorectal cancer (CRC) survi-
vors. Moreover, for stage I disease, which accounts for more than 30% of survivors, the guidelines are limited, and the use of surveil-
lance has not been well studied. Guidelines were changed in 2005 to include recommendations for computed tomography (CT)
surveillance in select patients, but the impact of these changes has not been explored. METHODS: A retrospective analysis of patients
who were identified in the Survival, Epidemiology, and End Results–Medicare database and underwent resection of stage I to III CRC
between 2001 and 2009 was performed. The receipt of guideline-determined sufficient surveillance, including office visits, colono-
scopy, carcinoembryonic antigen (CEA) testing, and CT imaging, in the 3 years after resection was evaluated. RESULTS: The study
included 23,990 colon cancer patients and 5665 rectal cancer patients. Rates of office visits and colonoscopy were high and stable
over the study period. Rates of CEA surveillance increased over the study period but remained low, even for stage III disease. Rates
of CT imaging increased gradually during the study period, but the 2005 guideline change had no effect. Stage II patients, including
high-risk patients, received surveillance at significantly lower rates than stage III patients despite similar recommendations. Con-
versely, up to 30% of stage I patients received nonrecommended CEA testing and CT imaging. CONCLUSIONS: There continues to be
substantial underuse of surveillance for CRC survivors and particularly for stage II patients, who constitute almost 40% of survivors.
The 2005 guideline change had a negligible impact on CT surveillance. Conversely, although guidelines are limited, many stage I
patients are receiving intensive surveillance. Cancer 2015;121:3525-33. VC 2015 American Cancer Society.
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INTRODUCTION
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in the United States, with almost 140,000 new
cases in 2014.1 Fortunately, survival is high; even with stage III disease, 5-year survival exceeds 50%. Because of improved
screening and treatment, mortality continues to decline. Because of the large number of CRC patients and the high and
improving long-term survival, there are now more than 1 million CRC survivors alive, with at least half of those eligible
for surveillance care, in the United States.1
Surveillance after treatment leads to early detection of recurrences or second primary CRCs and improves survival
for patients with stage II and III CRC.2-6 Surveillance entails office visits, colonoscopy, and serial carcinoembryonic anti-
gen (CEA) blood testing for up to 5 years after treatment. In 2005, recommendations by the American Society of Clinical
Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) added annual surveillance computed to-
mography (CT) scanning for at least 3 years after treatment for all stage III and select stage II patients.7-9 The most recent
ASCO update to the CRC surveillance guidelines in 2013 reinforced these recommendations and further suggested that
even more frequent CT imaging might be considered for patients deemed to be at high risk for recurrence.10 Results from
a recent trial suggest that stage I patients, who constitute more than 30% of the CRC survivor population, benefit from
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aggressive surveillance.11 Despite this, neither the ASCO
guidelines nor the NCCN guidelines comprehensively
address stage I surveillance.
Numerous population-based studies have examined
patient and geographic factors associated with underuse of
surveillance in the 1990s and early 2000s.2,12-14 Little is
known, however, about longitudinal trends in surveillance,
especially after the 2005 guideline change recommending
CT surveillance. In this study, we used data from a national
cancer registry combined with Medicare claims to examine
trends in CRC surveillance from 2001 through 2009 for
patients with stage I, II, and III CRC. We were interested
specifically in the association between the 2005 guideline
change and the use of surveillance CT imaging. In addition,
given the lack of formal recommendations, we evaluated
trends in surveillance for patients with stage I CRC.
MATERIALS AND METHODS
Cohort
We obtained data from the Survival, Epidemiology, and
End Results (SEER)–Medicare files for patients who
underwent surgical resection of stage I, II, or III invasive
colon or rectal adenocarcinoma between 2001 and
2009.15 Notably, for rectal cancer patients treated with
neoadjuvant radiochemotherapy, we included only
patients with documented pathologically staged disease.
In addition, to identify surveillance for CRC only, we
excluded patients for whom CRC was not the first pri-
mary cancer or who were diagnosed with any other cancer.
To fully capture claims, patients were also excluded if they
were enrolled in a health maintenance organization or
were not enrolled in Medicare Parts A and B for at least 1
year before their diagnosis or for any time during the
follow-up period. We excluded patients younger than 66
years or older than 99 years. Individuals younger than 65
years who are covered under Medicare are disabled or
have end-stage renal disease. Because of their unusual
characteristics, we did not include them in our analysis.
Surveillance
Subjects were considered to have had sufficient surveil-
lance according to the existing literature and the ASCO
and NCCN guidelines if they received the following serv-
ices during the first 3 surveillance years: 1) 2 office visits
per year; 2) 1 CT scan of the chest, abdomen, and pelvis
per year; and (c) 1 total colonoscopy. In addition, subjects
were required to have at least 2 blood tests for CEA per
year for the first 2 surveillance years. We recognize that
the use of CT was not included in surveillance recommen-
dations until 2005, and the imaging guidelines apply only
to stage III patients and select stage II patients. Neverthe-
less, to compare the use of surveillance in a uniform man-
ner across all years and stages, we used this common
definition of sufficient surveillance for all stage I, II, and
III patients. Sufficient nonimaging surveillance, defined
by the same criteria minus the CT scans, was also
explored.
In the published guidelines, yearly CT surveillance
is recommended for all stage III patients and stage II
patients with high-risk features.8,9 Risk factors that we
could identify from the SEER data were the grade of dis-
ease (well, moderately, and poorly differentiated or undif-
ferentiated) and the number of lymph nodes evaluated.
We defined a high-risk stage II cohort as patients with
poorly differentiated or undifferentiated tumors or
with fewer than 12 lymph nodes identified in the surgical
specimen. We analyzed rates of CT use in this group
separately.
To avoid capturing tests performed for diagnosis
rather than surveillance, eligibility for surveillance started
6 months after the operation. The surveillance periods
were defined as year 1 (postoperative months 7-18), year
2 (postoperative months 19-30), and year 3 (postoperative
months 31-42). We searched claims in the Medicare
National Claims History, outpatient, and Medicare Pro-
vider Analysis and Review files to identify relevantCurrent
Procedural Terminology and International Classification
of Diseases, Ninth Revision codes for surveillance tests
(Table 1). We counted office visits as surveillance only if
the provider specialty code associated with the visit indi-
cated a primary care, oncologic, or surgical specialty
because these are the specialties typically involved in CRC
surveillance. Codes for the same service on the same day
identified in more than 1 file were counted only once to
avoid duplications.
Claims data were available from January 1, 2000
through December 31, 2010. Patients were included in
each surveillance period–specific analysis only if they had
follow-up for the entire time period being studied. For
example, for 1-year surveillance, we included patients who
had at least 18months of follow-up from surgery to Decem-
ber 31, 2010. Thus, only patients who had surgery before
July 2007 were included in analyses of 3-year surveillance.
In addition, recognizing that patients at the end of life may
have had different patterns of care, we included for analysis
only patients who survived for 3.5 years after surgery or, for
those diagnosed after August 2008, were alive at the end of
the survival follow-up (February 28, 2012).
Finally, in an effort to identify testing used only for
surveillance, we excluded patients with evidence of
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recurrent disease during the 3.5-year surveillance period.
Laboratory testing and imaging studies are likely used
more frequently during the workup and treatment of re-
currence and would have inflated the surveillance rate if
they had been included in the analysis. Recurrence was
defined as the presence of codes for chemotherapy begin-
ning 1 year after surgical treatment. Adjuvant therapy
should be complete within 1 year of surgery, so chemo-
therapy outside this window was used as a marker for
recurrence.
Analysis
Patients’ receipt of each type of surveillance service was
measured as a binary indicator variable (yes/no) and mod-
eled with logistic regression as a function of the year of
diagnosis (measured as a set of binary indicators) and a set
of patient characteristics. The patient characteristics
included the cancer site (colon or rectal), sex, age, race/
ethnicity, marital status, and Charlson comorbidity score
(calculated on the basis of claims occurring during the 1
year before the index resection).16,17 We calculated
adjusted annual proportions of surveillance receipt by di-
agnosis year from the logistic regression results separately
for individual surveillance procedures for postoperative
surveillance years 1, 2, and 3.
We also compared the adjusted annual proportions
of patients receiving sufficient surveillance (according to
the aforementioned definitions) before and after the 2005
change in surveillance CT guidelines. For selected out-
comes, we calculated average annual rates of change as
slope coefficients from linear models of the adjusted sur-
veillance proportions regressed on a linear trend based on
TABLE 1. ICD-9 and CPT Codes for Identifying Surveillance Items
Category CPT/HCPCS Codes Description
Office visits 99201-99215,
99214-99245
Office visits
Colonoscopy 44388 Colonoscopy through stoma; diagnostic, with or without collection of specimen
44389 Colonoscopy through stoma, with biopsy, single or multiple
44392 Colonoscopy through stoma, with removal of tumor(s), polyp(s), or other lesions
by hot biopsy forceps or bipolar cautery
44393 Colonoscopy through stoma; with ablation of tumor(s), polyp(s), or other lesion(s)
not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique
44394 Colonoscopy through stoma; with removal of tumor(s), polyp(s), or other lesion(s)
by snare technique
45378 Colonoscopy, flexible, proximal to splenic flexure; diagnostic, with or without
collection of specimen(s) by brushing or washing, with or without colon
decompression (separate procedure)
45380 Colonoscopy, flexible, proximal to splenic flexure; with biopsy, single or multiple
45383 Colonoscopy, flexible, proximal to splenic flexure; with ablation of tumor(s),
polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps,
bipolar cautery or snare technique
45384 Colonoscopy, flexible, proximal to splenic flexure; with removal of tumor(s), polyp(s),
or other lesion(s) by hot biopsy forceps or bipolar cautery
45385 Colonoscopy, flexible, proximal to splenic flexure; with removal of tumor(s), polyp(s),
or other lesion(s) by snare technique
45391 Colonoscopy, flexible proximal to splenic flexure with endoscopic ultrasound examination
G0105 Colorectal cancer screening; colonoscopy on individual at high risk
G0120 Colorectal cancer screening; alternative to G0105, screening colonoscopy, barium enema
G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk
CEA 82378 CEA
CT imaging 71250 CT thorax, without contrast
71260 CT thorax, with contrast
71270 CT thorax, without contrast followed by contrast
71275 CT thorax—angiography
74150 CT abdomen, without contrast
74160 CT abdomen, with contrast
74170 CT abdomen, without contrast followed by contrast
74176 CT abdomen and pelvis, without contrast
74177 CT abdomen and pelvis, with contrast
74178 CT abdomen and pelvis, without contrast followed by contrast
72192 CT pelvis, without contrast
72193 CT pelvis, with contrast
72194 CT pelvis, without contrast followed by contrast
Abbreviations: CEA, carcinoembryonic antigen; CPT, Current Procedural Terminology; CT, computed tomography; HCPCS, Healthcare Common Procedure
Coding System; ICD-9, International Classification of Diseases, Ninth Revision.
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the year of diagnosis. Specific annual surveillance propor-
tions were compared between years withWald tests.
Notably, we analyzed colon cancer and rectal cancer
separately and together. The trends and rates of surveil-
lance were almost identical for colon and rectal cancers, so
only results based on the combined data are presented
here. The study was approved by the the Hospital of the
University of Pennsylvania IRB.
RESULTS
We identified 23,990 colon cancer patients and 5665 rec-
tal cancer patients with stage I, II, or III disease who
underwent surgical resection between 2001 and 2009 and
survived, without evidence of recurrence, at least 3.5 years
or to the end of follow-up (Fig. 1). The mean age of
patients in the cohort was 76.6 years; 38.5% had stage I
disease, 38.7% had stage II disease, and 22.7% had stage
III disease. The characteristics of the cohort by disease
stage are shown in Table 2.
Office Visits
Most patients met the recommendations for office visits
(Fig. 2A). Over the study period, there were no significant
changes over time in the rates of office visits among stage I
(P 5 .72), stage II (P 5 .59), or stage III patients (P 5
.49). Overall, stage III patients received recommended
office visits 78.5% of the time versus 69% and 67% for
stage II and stage I patients, respectively (P< .001).
Colonoscopy
Similarly high and stable rates of adherence were seen for
surveillance colonoscopy, but there was little difference
between stages (Fig. 2B). Among stage I patients, 76% in
2001 and 77% in 2007 underwent colonoscopy within
the 3-year surveillance period. The rates were essentially
the same for stage II and III patients (73.2% and 73.1%
overall, respectively).
CEA
Adherence to CEA testing was lower in comparison with
office visits and colonoscopy for all stages, although rates
increased over the study period (Fig. 2C). In 2001, 44%
of stage III patients met recommended CEA surveillance,
whereas 54% did in 2008; this indicated an average
increase of 1.7 percentage points per year (P < .001).
Among stage II patients, 26% of patients diagnosed in
2001 and 38% of patients diagnosed in 2008 received suf-
ficient CEA screening; this meant an average increase of
1.5 percentage points per year (P < .001). Although the
rates were lower, a similar trend was seen in stage I
patients. Use of CEA testing was significantly higher in
stage III patients versus stage II patients (P< .001). Stage
TABLE 2. Patient Demographics by Stage of Disease
Overall Stage I Stage II Stage III P
Cancer site, % (No.) <.001
Rectal 19 (5665) 25 (2847) 14 (1579) 18 (1239)
Colon 81 (23,990) 75 (8584) 86 (9904) 82 (5502)
Sex, % (No.) <.001
Female 58 (17,333) 57 (6474) 61 (6965) 58 (3894)
Male 42 (12,322) 43 (4957) 39 (4518) 42 (2847)
Marital status, % (No.) <.001
Not married 48 (14,157) 45 (5189) 50 (5797) 47 (3171)
Married 52 (15,498) 55 (6242) 50 (5686) 53 (3570)
Charlson comorbidity index score, % (No.) <.001
0 59.5 (17,639) 59.4 (6788) 58.6 (6729) 61.2 (4122)
1 23 (6845) 23.2 (2653) 23.5 (2693) 22.2 (1499)
2 8.3 (2451) 8.8 (1007) 8.0 (922) 7.7 (522)
31 9.2 (2720) 8.6 (983) 9.9 (1139) 8.9 (598)
Age, % (No.) <.001
66–70 y 21 (6197) 22.6 (2583) 19 (2127) 22 (1487)
71–75 y 24 (7023) 25.2 (2875) 22 (2538) 24 (1610)
76–80 y 24 (7229) 24.9 (2852) 24 (2785) 24 (1592)
81–85 y 19 (5708) 17.6 (2014) 21 (2413) 19 (1281)
861 y 12 (3498) 9.7 (1107) 14 (1620) 11 (771)
Race/ethnicity, % (No.) <.001
White 83.6 (24,791) 84.2 (9619) 84.4 (9690) 81.4 (5482)
Black 6.3 (1867) 6.0 (686) 6.3 (720) 6.8 (461)
Hispanic 4.4 (1294) 4.1 (469) 4.3 (493) 4.9 (332)
Asian 4.0 (1174) 3.8 (438) 3.5 (405) 4.9 (331)
Unknown 1.7 (529) 1.9 (219) 1.5 (175) 2.0 (135)
Sample size, n 29,655 11,431 11,483 6741
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I patients had the lowest rates of CEA testing, although
almost 20% underwent at least 2 CEA tests per year for
the first 2 years of surveillance.
CT
CT use varied by stage of disease (Fig. 3). Over the study pe-
riod, 52% of stage III patients underwent CT in surveillance
year 1, whereas 37% of stage II patients and 26% of stage I
patients did (P< .001). Only 18% of stage III patients, 9%
of stage II patients, and 5% of stage I patients underwent at
least 1 CT scan per year for 3 years (P< .001).
We also compared rates of CT surveillance between
stage III patients and high-risk stage II patients before and
after the 2005 inclusion of CT in the national surveillance
guidelines (Fig. 4). From 2005 to 2009, 58% of stage III
patients underwent a CT scan in surveillance year 1,
whereas 46% of high-risk stage II patients did (P5 .005).
During the same time period, 22% of stage III patients
received sufficient CT imaging for all 3 years, whereas
11% of high-risk stage II patients did (P< .001).
There was a significant increase in the use of CT
between 2001 and 2009, most notably in stage III patients
(Fig. 3). CT surveillance in year 1 increased on average by
1.2, 1.6, and 1.9 percentage points per year for stage I, II,
and III patients, respectively (P < .001 for each). Similar
trends were seen for years 2 and 3. The proportion of
patients undergoing at least 1 CT scan per year for all 3 years
also increased during the study period. In 2001, 13% of
stage III patients underwent at least 1 CT scan per year for 3
years, whereas 27% did in 2007; this translated into an aver-
age increase of 2.4 percentage points per year (P< .001).
We also analyzed the difference in CT use by diag-
nosis year versus the baseline year of 2004, the year before
the inclusion of CT surveillance in the guidelines (Fig. 3).
The sizes of the differences between 2001 and 2004 and
between 2004 and 2007 were similar. For example, in
stage III patients, receipt of 3-year sufficient CT surveil-
lance increased by 7.5 percentage points from 2001 to
2004 (P < .001). From 2004 to 2007, the increase was
7.2 percentage points (P 5 .025). Similar trends were
seen in the rate of CT use for individual surveillance years.
Overall Surveillance
The rate of sufficient nonimaging surveillance (office vis-
its plus colonoscopy and CEA) was low but increased
modestly between 2001 and 2007 (Fig. 5A). In all years,
stage III patients received sufficient nonimaging surveil-
lance significantly more frequently than stage II or I
patients. Between 2001 and 2007, sufficient nonimaging
surveillance increased annually by 1.2 percentage points
for stage III disease (P 5 .001), 1.0 percentage points for
stage II disease (P < .001), and 0.8 percentage points for
stage I disease (P< .001).
To assess adherence to the 2005 guideline changes,
we analyzed rates of sufficient surveillance with the inclu-
sion of CT for patients diagnosed in 2005 or later (Fig.
5B). Sufficient surveillance declined significantly across
all stages when CT was included, and this indicated poor
adherence to the imaging recommendations. From 2005
to 2007, after CT was included, roughly 15% to 20% of
stage III patients and 5% to 10% of stage II patients
received sufficient surveillance.
DISCUSSION
Using the SEER-Medicare linked database, we examined
CRC surveillance trends in the United States. Rates of
office visits were high and remained steady over time. The
rates of office visits reported here are slightly lower than
those in other published studies,2,12-14 likely because we
included only office visits associated with codes for primary
care, oncologic, or surgical specialties. Encouragingly, rates
of surveillance colonoscopy were also high and steady.
Figure 1. Flowchart demonstrating cohort creation.
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Rates of CEA testing were relatively low but rising. The use
of CT increased substantially over the study time period
but remained well below guideline recommendations.
Rates of sufficient surveillance and sufficient nonimag-
ing surveillance increased gradually but remained low for
stage II and III disease, especially when CT imaging was
included in the definition. The surveillance guidelines are
most explicit for stage III CRC, and this patient population,
not surprisingly, received surveillance testing at much higher
rates than the stage I and stage II populations. Even among
stage III patients, however, only 20% of patients diagnosed
after 2005 received sufficient surveillance at 3 years.
To our knowledge, no other study has examined the
rate of CT surveillance around the 2005 guideline change.
Our results show a gradual increase in the rates of CT
imaging across all disease stages between 2001 and 2009,
with no abrupt increase noted after 2005. In fact, there
was a greater increase in CT use during 2001-2004 than
2004-2007, and this suggests that the increase was poten-
tially driven by easier access to CT scans rather than a
response to changing guidelines.
We also looked at the use of surveillance in stage I
and stage II patients, who constitute the majority of the
survivor population but for whom surveillance guidelines
are less specific. The guidelines for CEA, colonoscopy,
and office visit surveillance for stage II patients are the
same as those for stage III patients.8,9 In 2007, however,
stage II patients were almost half as likely as stage III
patients to receive sufficient nonimaging surveillance.
The NCCN guidelines recommend annual CT sur-
veillance for stage II patients with a high risk of recur-
rence, which includes poorly differentiated histology,
<12 lymph nodes examined, lymphovascular invasion,
perineural invasion, perforation, and close margins.8,9
To evaluate this, we examined surveillance in stage II
patients and used differentiation and nodal examination
as a proxy for recurrence risk; we recognize that in prac-
tice other factors listed previously also play a role. The
rate of imaging surveillance for patients with high-risk
stage II disease was well below that for patients with stage
III disease. Because stage II patients make up almost
40% of the CRC survivor population, further studies
elucidating the patterns of surveillance based on specific
patient and tumor characteristics in this population
would be warranted. If even high-risk stage II patients
are receiving surveillance at such low rates, perhaps
Figure 2. Adjusted sufficient nonimaging surveillance (office visits, colonoscopy, and CEA) by diagnosis year and stage. CEA indi-
cates carcinoembryonic antigen.
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clarification of the guidelines with specific recommenda-
tions for subgroups of stage II patients is needed.
Stage I patients make up more than one-third of the
CRC survivor population, but recommendations for their
surveillance care are limited. The 2013 ASCO update spe-
cifically notes that the guidelines do not apply to stage I
patients. As expected, far fewer stage I patients underwent
surveillance testing than stage II or III patients did. Our
results show, however, that up to 30% of stage I patients
underwent CT scanning and CEA testing in surveillance
year 1. To prevent potential overuse or underuse of care
and to better guide providers caring for stage I patients in
the survivorship period, additional research is needed to
determine the benefits (if any) and costs of intensive sur-
veillance in these low-risk patients.
Our study is limited by reliance on administrative
claims data. We cannot know for certain the actual indica-
tion for the surveillance tests identified. If some of the
items captured were diagnostic and were not for surveil-
lance, the already low rates of surveillance that we have
demonstrated would be upper bound estimates, and the
true rates would be even lower. In addition, patients who
were morbidly ill from their cancer or other causes may
have received more or less surveillance testing because
their care was driven by their overriding medical condi-
tion. As such, we limited our analyses to those patients
who survived at least 3.5 years or to the end of our study
period to capture surveillance tests more accurately. In
addition, our analysis is limited to only those patients at
least 66 years of age who were covered by Medicare. Sur-
veillance patterns for CRC in those younger than 66 years
or in those with private insurance may look very different
than those in elderly Medicare patients. Despite this, the
median age of CRC diagnosis in the general population is
69 years, and well over 50% of patients diagnosed with
the disease are>65 years old, so these observations are ap-
plicable to a majority of the CRC patient population.18 In
addition, Medicare covers 93% of the population older
than 65 years, and almost 50% are covered only by Medi-
care.19 Thus, although patterns for the privately insured
may differ, our study sample represents a substantial sub-
set of the CRC patient population.
In conclusion, despite an absence of formal guide-
lines for surveillance care among patients with resected
stage I CRC, many of these patients have undergone in-
tensive surveillance, including annual CT imaging. Cur-
rently, the impact of intensive surveillance on stage I CRC
is unclear. Intensive surveillance could be beneficial in
Figure 3. Adjusted sufficient computed tomography by stage, diagnosis year, and surveillance year.
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Figure 4. Adjusted sufficient computed tomography for high-risk stage II patients versus all stage III patients by diagnosis year
and surveillance year.
Figure 5. Three-year adjusted sufficient surveillance by diagnosis year and stage. CT indicates computed tomography.
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improving overall survival through the detection of early
disease recurrence or second primary CRC. Conversely, it
could be harmful by leading to invasive tests that would
otherwise not be performed and potentially increasing
morbidity and health care costs. Additional research is
needed to determine optimal surveillance care for patients
with stage I CRC, especially because they make up more
than a third of the CRC survivor population.
Rates of recommended surveillance care were signifi-
cantly lower among stage II CRC patients (even high-risk
stage II patients) versus stage III patients. This gap between
guideline-recommended care and actual care is concerning
because very few stage II patients receive sufficient surveil-
lance with its attendant benefits. Perhaps more explicit
guidelines are needed for the population of stage II CRC
patients for whom intensive surveillance, including CT
imaging, is thought to be beneficial. Finally, even among
stage III CRC patients, for whom guidelines are the clear-
est, the rates of sufficient surveillance were notably low de-
spite a modest increase in use over the study period.
In an effort to address low rates of surveillance, the
Commission on Cancer recently advocated the develop-
ment of survivorship care plans created by the treating
cancer specialists.10 The commission recommends that
cancer providers deliver explicit plans, including surveil-
lance goals, to patients and, if necessary, patients’ primary
providers in an effort to guide patients’ survivorship care,
even when they are not, or cannot, be followed by their
specialty cancer providers. Perhaps adoption of such a
practice as a quality measure in cancer care will lead to an
increase in the low rate of guideline-adherent surveillance.
Although formal guidelines and specific care plans
may help providers deliver adequate surveillance, there are
likely other challenges in the provision of guideline-
concordant care. Systems factors such as ease of obtaining
surveillance testing, patient factors such as age, race, and
socioeconomic status, and geographic limitations likely all
contribute to the low rates of surveillance among CRC
survivors. Personalization of surveillance care by disease
stage and recurrence risk, in addition to further identifica-
tion of specific, modifiable barriers to guideline-
concordant surveillance, is also needed to improve
adherence to recommended surveillance in this large and
growing population of cancer survivors
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